Cargando…
A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells
HIV-1 replication capacity is an important characteristic to understand the replication competence of single variants or virus populations. It can further aid in the understanding of HIV-1 pathogenicity, disease progression, and drug resistance mutations. To effectively study RC, many assays have be...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000554/ https://www.ncbi.nlm.nih.gov/pubmed/33806576 http://dx.doi.org/10.3390/v13030404 |
_version_ | 1783671024746758144 |
---|---|
author | Rindler, Audrey E. Kuster, Herbert Neumann, Kathrin Leemann, Christine Braun, Dominique L. Metzner, Karin J. Günthard, Huldrych F. |
author_facet | Rindler, Audrey E. Kuster, Herbert Neumann, Kathrin Leemann, Christine Braun, Dominique L. Metzner, Karin J. Günthard, Huldrych F. |
author_sort | Rindler, Audrey E. |
collection | PubMed |
description | HIV-1 replication capacity is an important characteristic to understand the replication competence of single variants or virus populations. It can further aid in the understanding of HIV-1 pathogenicity, disease progression, and drug resistance mutations. To effectively study RC, many assays have been established. However, there is still demand for a high throughput replication capacity assay using primary cells which is robust and reproducible. In this study, we established such an assay and validated it using 346 primary HIV-1 isolates from patients enrolled in the Zurich Primary HIV Infection study (ZPHI) and two control viruses, HIV-1 JR-CSF(WT) and HIV-1 JR-CSF(K65R_M184V). Replication capacity was determined by measuring the viral growth on PBMCs over 10 days by longitudinally transferring cell culture supernatant to TZM-bl reporter cells. By utilizing the TZM-bl luciferase reporter assay, we determined replication capacity by measuring viral infectivity. The simplicity of the experimental setup allowed for all 346 primary HIV-1 isolates to be replicated at one time. Although the infectious input dose for each virus was normalized, a broad range of replication capacity values over 4 logs was observed. The approach was confirmed by two repeated experiments and we demonstrated that the reproducibility of the replication capacity values is statistically comparable between the two separate experiments. In summary, these results endorse our high throughput replication capacity assay as reproducible and robust and can be utilized for large scale HIV-1 replication capacity experiments in primary cells. |
format | Online Article Text |
id | pubmed-8000554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80005542021-03-28 A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells Rindler, Audrey E. Kuster, Herbert Neumann, Kathrin Leemann, Christine Braun, Dominique L. Metzner, Karin J. Günthard, Huldrych F. Viruses Article HIV-1 replication capacity is an important characteristic to understand the replication competence of single variants or virus populations. It can further aid in the understanding of HIV-1 pathogenicity, disease progression, and drug resistance mutations. To effectively study RC, many assays have been established. However, there is still demand for a high throughput replication capacity assay using primary cells which is robust and reproducible. In this study, we established such an assay and validated it using 346 primary HIV-1 isolates from patients enrolled in the Zurich Primary HIV Infection study (ZPHI) and two control viruses, HIV-1 JR-CSF(WT) and HIV-1 JR-CSF(K65R_M184V). Replication capacity was determined by measuring the viral growth on PBMCs over 10 days by longitudinally transferring cell culture supernatant to TZM-bl reporter cells. By utilizing the TZM-bl luciferase reporter assay, we determined replication capacity by measuring viral infectivity. The simplicity of the experimental setup allowed for all 346 primary HIV-1 isolates to be replicated at one time. Although the infectious input dose for each virus was normalized, a broad range of replication capacity values over 4 logs was observed. The approach was confirmed by two repeated experiments and we demonstrated that the reproducibility of the replication capacity values is statistically comparable between the two separate experiments. In summary, these results endorse our high throughput replication capacity assay as reproducible and robust and can be utilized for large scale HIV-1 replication capacity experiments in primary cells. MDPI 2021-03-04 /pmc/articles/PMC8000554/ /pubmed/33806576 http://dx.doi.org/10.3390/v13030404 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Rindler, Audrey E. Kuster, Herbert Neumann, Kathrin Leemann, Christine Braun, Dominique L. Metzner, Karin J. Günthard, Huldrych F. A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells |
title | A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells |
title_full | A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells |
title_fullStr | A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells |
title_full_unstemmed | A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells |
title_short | A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells |
title_sort | novel high throughput, parallel infection assay for determining the replication capacities of 346 primary hiv-1 isolates of the zurich primary hiv-1 infection study in primary cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000554/ https://www.ncbi.nlm.nih.gov/pubmed/33806576 http://dx.doi.org/10.3390/v13030404 |
work_keys_str_mv | AT rindleraudreye anovelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells AT kusterherbert anovelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells AT neumannkathrin anovelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells AT leemannchristine anovelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells AT braundominiquel anovelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells AT metznerkarinj anovelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells AT gunthardhuldrychf anovelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells AT rindleraudreye novelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells AT kusterherbert novelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells AT neumannkathrin novelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells AT leemannchristine novelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells AT braundominiquel novelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells AT metznerkarinj novelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells AT gunthardhuldrychf novelhighthroughputparallelinfectionassayfordeterminingthereplicationcapacitiesof346primaryhiv1isolatesofthezurichprimaryhiv1infectionstudyinprimarycells |